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Conclusions: The HAS-BLED score is predictive of hemor-
rhagic complications, adverse cardiovascular events, and
mortality in anticoagulated patients with AF.
Perspective: Some variables that are predictive of bleeding
(e.g., older age, renal impairment, prior stroke) also are pre-
dictive of thromboembolic events. This explains why the
HAS-BLED score is also predictive of adverse outcomes
related to thromboembolism. The results suggest that if the
HAS-BLED score is >4, it may be prudent to avoid oral
anticoagulant therapy since the risk of bleeding exceeds that
of thromboembolism.
Summary written by: Fred Morady, MD
Effect of Statins on Ventricular Tachyarrhythmia,
Cardiac Arrest, and Sudden Cardiac Death:
A Meta-Analysis of Published and Unpublished
Evidence From Randomized Trials
Rahimi K, Majoni W, Merhi A, Emberson J.
Eur Heart J 2012;Feb 3:[Epub ahead of print].
Study Question: Do statins prevent malignant ventricular tach-
yarrhythmias (VTs)?
Methods: This meta-analysis of randomized trials compared
statins to a placebo or usual care (29 trials, 113,568 sub-
jects), or compared different intensities of statin therapy (8
trials, 41,452 subjects). Unpublished data on VTs were
obtained when feasible.
Results: Data on VTs, cardiac arrest, and sudden cardiac
death (SCD) were available in 18, 12, and 30 trials, respec-
tively. Statins did not significantly reduce the risk of VTs
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Relation of the Has-Bled Bleeding Risk Score to
Major Bleeding, Cardiovascular Events and
Mortality in Anticoagulated Patients With Atrial
Fibrillation
Gallego P, Roldan V, Torregrosa JM, et al.
Circ Arrhythm Electrophysiol 2012;Feb 7:[Epub ahead of print].
Study Question: How accurately does the HAS-BLED bleed-
ing score predict major bleeds and cardiovascular events? 
Methods: The study subjects were 965 patients (median age
76 years) with atrial fibrillation (AF) anticoagulated with a
vitamin K antagonist for ≥6 months and with an interna-
tional normalized ratio (INR) of 2-3. The HAS-BLED
score consisted of 1 point for hypertension, abnormal
renal/liver function, stroke, bleeding history, labile INR, age
≥65 years, and use of drugs/alcohol. Cardiovascular end-
points were stroke/transient ischemic attack, embolism,
acute coronary syndrome, acute heart failure, and cardiac
death.
Results: During a median follow-up of 22 months, the
annual incidences of cardiovascular events, strokes, hemor-
rhagic events, intracranial hemorrhage, and mortality were
4.9%, 1.8%, 3.6%, 0.7%, and 4.5%. There was a monotonic
relationship between bleeding rate and HAS-BLED score.
The bleeding rate significantly exceeded the thromboem-
bolism rate when the HAS-BLED score was >4. The
HAS-BLED score had a c-statistic of 0.7 for bleeding, 0.58
for adverse cardiovascular events, and 0.62 for all-cause
mortality.
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choice for aortic valve stenosis in elderly patients with an
increased risk for surgery, with excellent functional recovery
of the patients, and overall low morbidity at 2 years. 
Perspective: This study suggests a considerable periprocedural
mortality but low mortality after 6 months; efficacy of the
treatment with persistent symptom relief; low morbidity at 2
years except for bleeding events; and good systolic valve func-
tion. Based on this and other studies, TAVI can be considered
the treatment of choice for aortic valve stenosis in elderly
patients with increased risk for surgery with a heart–lung
machine. Because outcomes were not compared with a control
group, future studies are indicated to prove an advantage over
conventional surgical AVR. 
Summary written by: Debabrata Mukherjee, MD
Quality, Not Volume, Determines Outcome of
Coronary Artery Bypass Surgery in a University-
Based Community Hospital Network
Kurlansky PA, Argenziano M, Dunton R, et al.
J Thorac Cardiovasc Surg 2012;143:287-293.
Study Question: What is the relationship between hospital and
surgeon coronary artery bypass grafting procedural volume,
mortality, morbidity, and National Quality Forum care
processes in a hospital quality improvement program?
Methods: The study population consisted of 2,218 patients
undergoing isolated coronary artery bypass grafting from
2007 to 2009 in a university-based quality improvement pro-
gram that emphasizes involvement of all surgeons in the
academic quality endeavor. The endpoints included opera-
tive mortality, major morbidity, and National Quality
Forum-endorsed process measures, as defined by the Society
of Thoracic Surgeons. The procedural volume was analyzed
using general estimating equations, which accounted for
clustering effects and were adjusted for Society of Thoracic
Surgeons risk scores and the propensity for operation in a
low- versus high-volume program. 
Results: The annual program volume ranged from 67 to 292
(median, 136) and surgeon volume from 1 to 124 (median,
58). The mortality rate among the hospitals was 0.47% to
2.23% (0.8% overall), and the observed/expected mortality
ranged from 0 to 1.20 (0.41 overall). When comparing low-
(<200 cases/year) and high-volume centers, no difference
was found in the mortality (odds ratio [OR], 1.08), morbid-
ity (OR, 1.34), or any of the medication process measures.
No difference was found in mortality (OR, 1.59), morbidity
(OR, 1.20), or medication failure (OR, 0.57) between the
high- and low-volume surgeons (<87). After adjustment for
the Society of Thoracic Surgeons risk score and the propen-
sity score, no association was found for hospital or surgeon
volume with mortality or morbidity. However, a lack of
compliance with National Quality Forum measures was
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or cardiac arrest. Statin therapy was associated with a sig-
nificant 11% reduction in the risk of SCD.
Conclusions: Statins modestly reduce the risk of SCD, but
do not prevent VTs or cardiac arrest.
Perspective: These results suggest that the mechanism by
which statins lower the risk of SCD is by prevention of
acute coronary events, not by a primary antiarrhythmic
effect. In contrast, prior studies, most nonrandomized,
reported that statins reduce the risk of VTs by ~30%. A
strength of the present study is that only randomized trials
were analyzed. Further, much of the data were previously
unpublished and obtained directly from the investigators,
eliminating publication bias.
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Beyond the Short-Term: Clinical Outcome and
Valve Performance 2 Years After Transcatheter
Aortic Valve Implantation in 227 Patients
Bleiziffer S, Mazzitelli D, Opitz A, et al.
J Thorac Cardiovasc Surg 2012;143:310-317.
Study Question: What is the long-term follow-up of clinical
and echocardiographic results after transcatheter aortic valve
implantation (TAVI)? 
Methods: Patients’ mean age was 81 ± 7 years, 59% were
female, mean European System for Cardiac Operative Risk
Evaluation was 21% ± 14%, mean Society of Thoracic
Surgeons score was 7% ± 5%, and access routes were trans-
femoral (n = 164), transapical (n = 54), axillary (n = 5), or
transaortic (n = 4). A CoreValve (Medtronic Inc.) prosthesis
was implanted in 174 patients, and a SAPIEN prosthesis
(Edwards Lifesciences) in 53 patients. Clinical and echocar-
diographic investigations were performed at 6 months, 1
year, and 2 years.
Results: Survival was 88.5% at 30 days, 75.9% at 6 months,
74.5% at 1 year, and 64.4% at 2 years. Patients improved
significantly in New York Heart Association class after 6
months (from 3.2 ± 0.5 to 1.7 ± 0.7, p < 0.001) and up to 2
years (1.9 ± 0.7). Cumulative incidences of myocardial
infarction, stroke, and life-threatening or major bleeding
were 2.7%, 6.2%, and 16.2% at 2 years, respectively. The
postprocedural mean transprosthetic gradient was 12 ± 4
mm Hg for all valves and did not change up to 2 years, and
the effective orifice area was 1.5 ± 0.4 cm2 with no change
over 2 years of follow-up. Moderate or severe prosthetic
regurgitation was present in 8% of patients at 2 years. In 6%
of patients, the paravalvular or valvular regurgitation grade
increased significantly over time.
Conclusions: TAVI may be considered the treatment of
responses. Risk stratification for males might also be better
assessed by focusing on the paternal history of CAD. If con-
firmed in other populations/databases, these exciting results
may eventually lead to new therapeutic targets for prevention
of CAD.
Summary written by: Daniel T. Eitzman, MD
Effects of Age on Long-Term Outcomes After a
Routine Invasive or Selective Invasive Strategy in
Patients Presenting With Non-ST Segment
Elevation Acute Coronary Syndromes: A
Collaborative Analysis of Individual Data From the
FRISC II - ICTUS - RITA-3 (FIR) Trials
Damman P, Clayton T, Wallentin L, et al.
Heart 2012;98:207-213.
Study Question: Does age influence the risk-benefit ratio of
early invasive versus selective invasive strategy in patients pre-
senting with non–ST-elevation acute coronary syndromes
(NSTE-ACS)?
Methods: The authors performed a pooled patient-level meta-
analysis of FRISC II, ICTUS, and RITA-3 studies.
Unadjusted and adjusted hazard ratios were calculated by
Cox regression, with adjustments for variables associated
with age and outcomes. The main outcome was 5-year car-
diovascular death or myocardial infarction (MI) following
routine invasive versus selective invasive management. 
Results: The combined data set had 5,467 patients. At 5-year
follow-up, 74.1% in the early invasive arm underwent revas-
cularization by percutaneous coronary intervention or
CABG, whereas 49.6% underwent revascularization in the
selective invasive strategy group. The routine invasive strat-
egy was associated with a lower hazard of death or MI in
patients ages 65-74 years (hazard ratio [HR], 0.72) and
those ages ≥75 years (HR, 0.71), but not in those ages <65
years (HR, 1.11), p = 0.001 for interaction between treat-
ment strategy and age. The interaction was driven by an
excess of early MIs in patients <65 years of age. Overall,
there was no difference in mortality. The benefits were
smaller for women than for men (p = 0.009 for interaction). 
Conclusions: The benefit of early invasive strategy was attenu-
ated in younger patients with NSTE-ACS.
Perspective: Although this study found benefit of early invasive
strategy in younger patients due to an excess of MIs, long-
term, there was no difference in survival among young
patients treated with an early or selective invasive strategy.
More importantly, older patients had significantly better out-
come with an early invasive approach, suggesting that age
alone should not be a bar to an invasive approach in patients
with ACS.
Summary written by: Hitinder S. Gurm, MBBS
highly predictive of morbidity (OR, 1.51), regardless of vol-
ume, even after adjustment for predicted risk. 
Conclusions: In a hospital quality improvement program,
excellent surgical results can be obtained in relatively low-
volume programs.
Perspective: A notable and somewhat unique study observation
is the correlation of process measures with outcomes that are
totally unrelated to the specific processes addressed. A mean-
ingful university affiliation might also represent a new quality
paradigm for cardiac surgery in the community hospital set-
ting. It is important to note that the authors did not examine
effects of very low-volume operators or centers, where the
results might be different.
Summary written by: Debabrata Mukherjee, MD
General Cardiology
Inheritance of Coronary Artery Disease in Men:
An Analysis of the Role of the Y Chromosome
Charchar FJ, Bloomer LD, Barnes TA, et al.
Lancet 2012;Feb 8:[Epub ahead of print].
Study Question: Does the Y chromosome contribute to coronary
artery (CAD) risk in males? 
Methods: Genetic markers on the Y chromosome were used
to group 3,233 unrelated men (from the BHF-FHS,
WOSCOPS, and Cardiogenics Study) into different hap-
logroups. Associations were then examined between CAD
risk and common Y haplogroups. In addition, a functional
analysis of Y chromosome effects on monocyte and
macrophage transcriptomes in British men from the
Cardiogenics Study was performed. 
Results: Nine haplogroups were identified, but two hap-
logroups (R1b1b2 and I) accounted for 90% of the Y
chromosome variants among British men. Carriers of hap-
logroup I had about a 50% higher age-adjusted independent
risk of CAD than other Y chromosome lineages (odds ratio,
1.56; 95% confidence interval, 1.24-1.97; p = 0.0002).
Analysis of macrophage transcriptomes in the Cardiogenics
Study revealed that 19 molecular pathways showing strong
differential expression between men with haplogroup I and
other lineages of the Y chromosome were interconnected by
common genes related to inflammation and immunity.
Conclusions: The human Y chromosome is associated with
risk of CAD in men of European ancestry, possibly through
interactions of immunity and inflammation.
Perspective: The increased risk of age-adjusted CAD in men is
largely unexplained. This study indicates that increased male
risk of CAD could be mediated by genes on the Y chromo-
some and could be related to exaggerated adaptive immune
JACC Vol. 59, No. 14, 2012
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Reliable Identification of ‘Truly Low’
Thromboembolic Risk in Patients Initially
Diagnosed With ‘Lone’ Atrial Fibrillation:
The Belgrade Atrial Fibrillation Study
Potpara TS, Polovina MM, Licina MM, et al.
Circ Arrhythm Electrophysiol 2012;Feb 8:[Epub ahead of print].
Study Question: What is the predictive ability of the
CHA2DS2-VASc, CHADS2, and van Walraven risk stratifi-
cation schemes in a cohort of ‘lone’ AF patients with a
12-year follow-up? 
Methods: The investigators conducted a registry-based,
observational cohort study of 345 patients initially diag-
nosed with ‘lone’ AF between 1992 and 2007. A
multivariable logistic regression analysis was used to study
the relationship between clinical characteristics, clinical type
of AF, and van Walraven, CHADS2, and CHA2DS2-VASc
scores of 0 with the use of oral anticoagulation during fol-
low-up. 
Results: At baseline, all patients had CHADS2 and van
Walraven scores of 0, and 75.9% had a CHA2DS2-VASc
score = 0. During follow-up (or within a year prior to
stroke), 66.1%, 67.8%, and 43.5% retained scores of 0 for
all. The overall rate of ischemic stroke was 0.19 per 100
patient-years. In the multivariable analysis, only the
CHA2DS2-VASc score of 0 was significantly related to the
absence of stroke (p = 0.008). Only the CHA2DS2-VASc
score had a significant prediction ability (p = 0.031). 
Conclusions: The CHA2DS2-VASc score reliably identified
the ‘lone’ AF patients who were at ‘truly low risk’ for
thromboembolism, and was the only tested risk stratifica-
tion scheme with a significant predictive ability for
thromboembolism amongst lone AF patients. 
Perspective: In the present study, a CHA2DS2-VASc score of
0 had the best predictive value for the absence of ischemic
stroke in ‘lone’ AF patients compared to CHADS2 and van
Walraven scores of 0. This is the largest validation of these
scores in a prospective cohort of patients with first-diagnosed
‘lone’ AF, with the diagnostic criteria for ‘lone’ AF being
strictly applied. Due to the dynamic nature of stroke risk fac-
tors, thromboembolic risk of an AF patient must be regularly
re-assessed during the follow-up, even if the baseline stroke
risk was ‘truly low.’ Greater efforts should be made to identify
AF patients with the ‘truly low risk’ who would need no
antithrombotic therapy at all, whilst all other AF patients
with one or more stroke risk factors should be considered for
oral anticoagulation.
Summary written by: Debabrata Mukherjee, MD
Oral Pharmacologic Treatment of Type 2 Diabetes
Mellitus: A Clinical Practice Guideline From the
American College of Physicians
Qaseem A, Humphrey LL, Sweet DE, et al.
Ann Intern Med 2012;156:218-231.
Perspective: The following are 10 points to remember about
this clinical practice guideline from the American College of
Physicians (ACP). 
1: Type 2 diabetes mellitus (DM) affects over 90% of
patients with diabetes and ~25.8 million adults in the United
States. Currently, 11 classes of drugs are approved by the
Food and Drug Administration (FDA) for the treatment of
hyperglycemia for DM; ~145 take insulin and an oral med-
ication, and 58% take an oral medication for control of
hyperglycemia. 
2: Based on a review of all clinical trials and cohorts, ACP
recommends that clinicians add oral pharmacologic therapy
in patients diagnosed with type 2 DM when lifestyle modifi-
cations, including diet, exercise, and weight loss, have failed
to adequately improve hyperglycemia (Grade: strong recom-
mendation; high-quality evidence). 
3: A review of prior studies suggests that clinicians prescribe
monotherapy with metformin for initial pharmacologic ther-
apy to treat most patients with type 2 diabetes (Grade:
strong recommendation; high-quality evidence). 
4: Metformin appears more effective than other medications as
monotherapy as well as when used in combination therapy
with another agent for reducing glycemic hemoglobin levels,
body weight, and plasma lipid levels. 
5: Regarding total and cardiovascular mortality, it is currently
difficult to draw conclusions about the comparative effective-
ness of type 2 DM medications due to low-quality or
insufficient evidence. 
6: The risk for hypoglycemia is increased with sulfonylureas
compared to metformin or thiazolidinediones. The combina-
tion of metformin plus sulfonylureas is associated with 6
times more risk for hypoglycemia than the combination of
metformin plus thiazolidinediones. 
7: Metformin is associated with an increased risk for gas-
trointestinal side effects. Thiazolidinediones are associated
with an increased risk for heart failure, and rosiglitazone and
pioglitazone are contraindicated in patients with serious
heart failure. 
8: Metformin is contraindicated in patients with impaired kid-
ney function, decreased tissue perfusion or hemodynamic
instability, liver disease, alcohol abuse, heart failure, and any
condition that might lead to lactic acidosis. 
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Effect of Cardiac Resynchronization Therapy in
Patients Without Left Ventricular Dyssynchrony
Auger D, Bleeker GB, Bertini M, et al.
Eur Heart J 2012;Jan 24:[Epub ahead of print].
Study Question: Does cardiac resynchronization therapy (CRT)
impact survival in patients with left ventricular (LV) dyssyn-
chrony at baseline? 
Methods: This was a cohort study of 290 patients with New
York Heart Association (NYHA) class III/IV heart failure,
left ventricular ejection fraction (LVEF) ≤35%, and a QRS
duration ≥120 ms without LV dyssynchrony. LV dyssyn-
chrony was measured by tissue Doppler echocardiogram
prior to CRT implant, and was defined as the maximum
delay between peak systolic velocities of the septal and lateral
walls. All patients had maximum delay <60 ms prior to CRT
implant. Atrio- but not interventricular delay was optimized
24 hours after device implant. After 48 hours of CRT,
patients were divided into two groups based on sample
median LV dyssynchrony measures: induced LV dyssyn-
chrony (≥40 ms) and noninduced dyssynchrony (<40 ms).
Survival was assessed based on LV dyssynchrony grouping
after CRT implant.
Results: At baseline, the median  LV dyssynchrony measure
was 22 ms, 69% had a left bundle branch block, and 45%
had a QRS <150 ms. Of the 290 patients, 50% had induced
LV dyssynchrony 48 hours after CRT. Compared with base-
line, LV dyssynchrony increased to 40 ms at 48 hours and 40
ms after 6 months of follow-up (p < 0.001). A CRT
response (≥15% decrease in LV end-systolic volume)
occurred in 93% of patients without induced dyssynchrony
compared with only 51% of those with induced dyssynchrony
(p < 0.001). There were 73 deaths (25%) over 34 months of
median follow-up. At 1 and 2 years, mortality in the induced
dyssynchrony group (10% and 17%, respectively) was higher
than in those without induced dyssynchrony (3% and 8%,
respectively). Induced LV dyssynchrony after CRT was asso-
ciated with a significantly (adjusted hazard ratio, 1.25 per 25
ms) higher risk of death on follow-up. 
Conclusions: Induction of LV dyssynchrony may lead to worse
outcome in patients with systolic heart failure.
Perspective: This novel analysis examined the impact of induc-
ing dyssynchrony in those undergoing CRT without
echocardiographic evidence of dyssynchrony preimplant.
Overall, mortality was not high, and almost half had a QRS
<150 ms prior to implant. Mortality was apparently higher in
those with induced dyssychrony after CRT implant, and the
survival curves showed marked separation after 2 years of fol-
low-up. This study raises several questions including: Is
survival worse in patients with induced dyssynchrony compared
with those not receiving any CRT? 
Summary written by: Jennifer Ann Cowger, MD, MS
9: Current evidence is not sufficient to show any difference
in effectiveness among various medications across subgroups
of adults. 
10: The ACP recommends that clinicians add a second agent
to metformin to treat patients with persistent hyperglycemia
when lifestyle modifications and monotherapy with metformin
fail to control hyperglycemia (Grade: strong recommendation;
high-quality evidence).
Summary written by: Elizabeth A. Jackson, MD
Heart Failure/Transplant
Truncations of Titin Causing Dilated
Cardiomyopathy
Herman DS, Lam L, Taylor MR, et al.
N Engl J Med 2012;366:619-628.
Study Question: How frequent are titin (TTN) mutations in
patients with dilated cardiomyopathy (DCM)?
Methods: The gene for TTN was analyzed in 312 subjects
with DCM, 231 subjects with HCM, and 249 controls
using next-generation or dideoxy sequencing. Gene variants
and clinical phenotypes were analyzed for cosegregation in
families. 
Results: A total of 72 unique mutations (25 nonsense, 23
frameshift, 23 splicing, and 1 large tandem insertion) that
altered full-length TTN were identified. The frequency of
TTN mutations was significantly higher among subjects
with DCM (27%) compared with HCM (1%) or controls
(3%). TTN mutations cosegregated with DCM in families
with high (>95%) penetrance after the age of 40 years. The
rates of cardiac outcomes were similar between subjects with
and without TTN mutations, but adverse events occurred
earlier in male mutation carriers than in female carriers.
Conclusions: TTN truncating mutations are a common cause
of DCM, occurring in ~25% of familial cases of idiopathic
DCM and 18% of sporadic cases. Incorporation of sequenc-
ing approaches that detect TTN truncations into genetic
testing for DCM should increase test sensitivity, allowing
earlier diagnosis and therapeutic intervention for many
patients with DCM. 
Perspective: Because TTN is encoded by a giant gene, sequenc-
ing analysis for TTN mutations in cardiomyopathies has been
incomplete. Using modern sequencing methods in a large
affected patient population, the investigators have now estab-
lished that TTN truncating mutations are the most common
genetic cause of DCM. In addition to providing biological
insight into the pathophysiology of DCM, these findings have
important implications for mutation analysis in patients with
DCM and family screening.
Summary written by: Daniel T. Eitzman, MD
JACC Vol. 59, No. 14, 2012
April 3, 2012:1255-62
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Cost Effectiveness of Transcatheter Aortic Valve
Replacement Compared With Standard Care
Among Inoperable Patients With Severe Aortic
Stenosis: Results From The PARTNER Trial
(Cohort B)
Reynolds MR, Magnuson EA, Wang K, et al.
Circulation 2012;Feb 3:[Epub ahead of print].
Study Question: What are the costs and cost-effectiveness of
transcatheter aortic valve replacement (TAVR) compared
with standard therapy? 
Methods: The PARTNER trial randomized patients with
symptomatic, severe aortic stenosis who were not candidates
for surgery to TAVR (n = 179) or standard therapy (n =
179). Empirical data regarding survival, quality of life, med-
ical resource use, and hospital costs were collected during
the trial and used to project life expectancy, quality-adjusted
life expectancy, and lifetime medical care costs in order to
estimate the incremental cost-effectiveness of TAVR from a
US perspective. 
Results: For patients treated with TAVR, mean costs for the
initial procedure and hospitalization were $42,806 and
$78,542, respectively. Follow-up costs through 12 months
were lower with TAVR ($29,289 vs. $53,621) due to
reduced hospitalization rates, but cumulative 1-year costs
remained higher ($106,076 vs. $53,621). Over a patient’s
lifetime, TAVR would increase discounted life expectancy
by 1.6 years (1.3 QALYs) at an incremental cost of $79,837.
The incremental cost-effectiveness ratio for TAVR was thus
estimated at $50,200 per year of life gained or $61,889 per
QALY gained. These results were stable across a broad
range of uncertainty and sensitivity analyses. 
Conclusions: For patients with severe aortic stenosis who are
not candidates for surgery, TAVR increases life expectancy
at an incremental cost per life-year gained well within
accepted values for commonly used cardiovascular technolo-
gies. 
Perspective: Additional studies are indicated to evaluate the
cost-effectiveness of TAVR for other lower-risk patient
populations, and when compared with other treatment
strategies (e.g., surgical AVR).
Overall, the current study suggests that TAVR may be a
good value in properly selected symptomatic patients with
aortic stenosis who are at too high a risk to have surgical
AVR.
Summary written by: Debabrata Mukherjee, MD
Noninvasive Cardiology
Age- and Gender-Specific Differences in the
Prognostic Value of CT Coronary Angiography
Yiu KH, de Graaf FR, Schuijf JD, et al.
Heart 2012;98:232-237.
Study Question: Does the prognostic value of computed
tomography coronary angiography (CTA) vary by age and
gender? 
Methods: This was a multicenter prospective study using a
registry of patients who had undergone CTA for suspected
coronary artery disease (CAD). Patients were stratified into
four groups by age and gender (males vs. females, and age
<60 vs. 60 or greater). Follow-up data were collected by
clinical visits or standardized telephone interviews with each
patient, a direct relative, or with the referring doctor to dis-
cuss symptoms. The primary endpoint was cardiac death,
and nonfatal myocardial infarction defined based on criteria
of typical angina, elevated cardiac enzyme levels, and typical
changes on the electrocardiogram. 
Results: A total of 2,432 patients underwent CTA; 56%
were male. The mean age was 57 ± 12 years. Males were
more likely to have a higher incidence of diabetes and
smoking history, whereas females were more likely to be
older, have hypertension, and have family history of CAD.
A total of 2,097 patients were referred for CTA, owing to
the presence of symptoms, whereas the remaining 335
patients were asymptomatic. The majority presented with
an intermediate pretest likelihood, whereas female patients
had a slightly higher frequency of low pretest likelihood. By
CTA, 41% of patients had no CAD, 31% had nonsignifi-
cant CAD, and 28% had significant CAD. Over a median
follow-up of 819 days, cardiovascular events occurred in
2.4% of patients. The annualized event rate was 1.1% in the
total population. In patients ages <60 years, the annualized
event rate of male and female patients was 0.6% and 0.5%,
respectively. Among patients ages ≥60 years, the annualized
event rate was 1.9% in male and 1.1% in female patients.
Observations on CTA predicted events in male patients,
both ages <60 and ≥60 years, and in female patients ages
≥60 years. However, CTA provided limited prognostic
value in female patients ages <60 years.
Conclusions: CTA was of limited predictive value among
females under the age of 60 years, as compared to male
patients of any age or females 60 years or older.
Perspective: Although longer-term follow-up will add to this
information, the data presented here are clinically useful
and suggest that young women, particularly those with few
cardiovascular disease risk factors, have little prognostic
information to gain from such testing.
Summary written by: Elizabeth A. Jackson, MD 
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Prevention/Vascular
Prevalence of Obesity and Trends in Body Mass
Index Among US Children and Adolescents,
1999-2010
Ogden CL, Carroll MD, Kit BK, Flegal KM.
JAMA 2012;307:483-490.
Study Question: What are the current estimates for obesity
prevalence among children and adolescents residing in the
United States for 2009-2010?
Methods: This was a cross-sectional analysis of a representa-
tive sample of adults residing in the United States from the
National Health and Nutrition Examination Survey
(NHANES) 2009-2010. The main outcome measures were
prevalence of high weight-for-recumbent length (≥95th per-
centile on the growth charts) among infants and toddlers
from birth to 2 years of age, and obesity (body mass index
[BMI], ≥95th percentile of the BMI-for-age growth charts)
among children and adolescents ages 2 through 19 years.
Analyses of trends in obesity by sex and race/ethnicity, and
analyses of trends in BMI within sex-specific age groups
were examined for six survey periods over 12 years.
Results: A total of 4,111 children and adolescents were
included. In 2009-2010, 9.7% of infants and toddlers had a
high weight-for-recumbent length. In the same time period,
16.9% of children and adolescents from 2 through 19 years
of age were obese. There was no difference in obesity preva-
lence among males (p = 0.62) or females (p = 0.65) between
2007-2008 and 2009-2010. The trend analyses over a 12-
year period indicated a significant increase in obesity
prevalence between 1999-2000 and 2009-2010 in males ages
2 through 19 years, but not in females. There was a signifi-
cant increase in BMI among adolescent males ages 12
through 19 years (p = 0.04), but not among any other age
group or among females. 
Conclusions: In 2009-2010, the prevalence of obesity in
children and adolescents was 16.9%. The prevalence has not
changed compared to data from 2007-2008.
Perspective: These data are encouraging in that no increase
in the prevalence of obesity was observed from 2007
through 2010, and that females do not appear to have
increases in obesity over the 12-year period examined.
However, understanding factors related to the increases in
obesity seen among males is required to prevent further
adverse trends in this group.
Summary written by: Elizabeth A. Jackson, MD 
Main Air Pollutants and Myocardial Infarction:
A Systematic Review and Meta-Analysis
Mustafic H, Jabre P, Caussin C, et al.
JAMA 2012;307:713-721.
Study Question: What is the association between short-term
exposure to major air pollutants (ozone, carbon monoxide,
nitrogen dioxide, sulfur dioxide, and particulate matter ≤10
μm [PM10] and ≤2.5 μm [PM2.5] in diameter) on myocar-
dial infarction (MI) risk? 
Methods: EMBASE, Ovid MEDLINE in-process and other
nonindexed citations, and Ovid MEDLINE (between 1948
and November 28, 2011), and EBM Reviews–Cochrane
Central Register of Controlled Trials and EBM Reviews–
Cochrane Database of Systematic Reviews (between 2005
and November 28, 2011) were searched for a combination
of keywords related to the type of exposure (air pollution,
ozone, carbon monoxide, nitrogen dioxide, sulfur dioxide,
PM10, and PM2.5) and to the type of outcome (MI, heart
attack, acute coronary syndrome). Two independent review-
ers selected studies using original data and investigating the
association between short-term exposure (up to 7 days) to
one or more air pollutants and subsequent MI risk.
Descriptive and quantitative information was extracted from
each selected study. Using a random-effects model, relative
risks (RRs) and 95% confidence intervals (CIs) were calcu-
lated for each increment of 10 μg/m3 in pollutant
concentration, except for carbon monoxide, an increase of 1
mg/m3 was considered. 
Results: After screening 117 studies, 34 were identified. All
the main air pollutants, except ozone, were significantly
associated with an increase in MI risk (carbon monoxide:
1.048; 95% CI, 1.026-1.070; nitrogen dioxide: 1.011; 95%
CI, 1.006-1.016; sulfur dioxide: 1.010; 95% CI, 1.003-
1.017; PM10: 1.006; 95% CI, 1.002-1.009; and PM2.5 :
1.025; 95% CI, 1.015-1.036). For ozone, the RR was 1.003
(95% CI, 0.997-1.010; p = 0.36). Subgroup analyses pro-
vided results comparable with those of the overall analyses.
Population-attributable fractions ranged between 0.6% and
4.5%, depending on the air pollutant. 
Conclusions: All the main air pollutants, with the exception of
ozone, were significantly associated with a near-term increase
in MI risk.
Perspective: Although the calculated relative risks in this
study were relatively low, the population-attributable frac-
tions were not negligible because the majority of the
population is exposed to air pollution in industrialized
countries. Additional prospective research is indicated to
determine whether interventions that effectively improve air
quality are associated with a decreased incidence of MI and
other cardiovascular conditions.
Summary written by: Debabrata Mukherjee, MD
JACC Vol. 59, No. 14, 2012
April 3, 2012:1255-62
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Moderate to Vigorous Physical Activity and
Sedentary Time and Cardiometabolic Risk Factors in
Children and Adolescents
Ekelund U, Luan J, Sherar LB, Esliger DW, Griew P, Cooper A, on
behalf of the International Children's Accelerometry Database
(ICAD) Collaborators.
JAMA 2012;307:704-712.
Study Question: Do physical activity and sedentary time impact
cardiometabolic factors in healthy children?
Methods: This study used data pooled from the International
Children’s Accelerometry Database. A total of 14 studies
conducted between 1998 and 2009, with 20,871 children
(ages 4-18 years), were included. Physical activity and seden-
tary time were measured through accelerometers. Primary
outcomes included waist circumference, systolic blood pres-
sure, fasting triglycerides, high-density lipoprotein
cholesterol, and insulin.
Results: The number of minutes per day of sedentary time
averaged 354 minutes, whereas moderate to vigorous physi-
cal activity averaged 30 minutes. Time spent in performing
moderate to vigorous activity was independently associated
with several cardiometabolic outcomes after controlling for
variables including age, gender, and waist circumference. In
contrast, time spent in sedentary activities was not associated
with cardiometabolic factor after adjusting for moderate to
vigorous physical activity. Mean differences in waist circum-
ference between the bottom and top tertiles of moderate to
vigorous physical activity were 5.6 cm for high sedentary
time and 3.6 cm for low sedentary time. Mean differences in
systolic blood pressure for high and low sedentary time were
0.7 mm Hg and 2.5 mm Hg, and for high-density lipopro-
tein cholesterol, differences were −2.6 mg/dl and −4.5 mg/dl,
respectively. Differences for insulin and triglycerides demon-
strated similar patterns. Those in the top tertile of moderate
to vigorous physical activity accumulated more than 35 min-
utes per day in this intensity level compared with fewer than
18 minutes per day for those in the bottom tertile. 
Conclusions: Higher levels of moderate to vigorous physical
activity time by children and adolescents was associated with
better cardiometabolic risk factors regardless of the amount of
sedentary time.
Perspective: These data highlight the importance of regular
physical activity. Given the popularity of sedentary pursuits
(such as video games) among children and adolescents, find-
ing time for moderate to vigorous activity, such as with
regular gym classes, is of public health importance.
Summary written by: Elizabeth A. Jackson, MD
Prevalence of Obesity and Trends in the Distribution
of Body Mass Index Among US Adults, 1999-2010
Flegal KM, Carroll MD, Kit BK, Ogden CL.
JAMA 2012;307:491-497.
Study Question: What are the current estimates for obesity
prevalence among adults residing in the United States?
Methods: This was a cross-sectional analysis of a representa-
tive sample of adults residing in the United States from the
National Health and Nutrition Examination Survey
(NHANES) 2009-2010. Height and weight were measured
in a standardized manner and compared to data from men
and women included in the NHANES 1999-2008 data.
The primary outcomes were prevalence of obesity and mean
body mass index (BMI).
Results: A total of 5,926 men and women were included in
the 2009-2010 cohort, which was compared to 22,847 men
and women in the 1999-2008 NHANES cohorts. In 2009-
2010, the age-adjusted mean BMI was 28.7 for men and
28.7 for women. Median BMI was 27.8 for men and 27.3
for women. The age-adjusted prevalence of obesity was
35.5% among adult men and 35.8% among adult women.
From 1999 through 2010, obesity showed no significant
increase among women overall (p = 0.07), but increases
were statistically significant for non-Hispanic black women
(p = 0.04) and Mexican American women (p = 0.046). For
men, there was a significant linear trend (p < 0.001) over
the 12-year period. For both men and women, the most
recent 2 years (2009-2010) did not differ significantly (p =
0.08 for men or p = 0.24 for women) from the previous 6
years. Trends in BMI were similar to obesity trends.
Conclusions: In 2009-2010, the prevalence of obesity in US
adults was 35.5% for men and 35.8% for women, with no sig-
nificant changes compared to data from 2003 to 2008.
Perspective: As with the NHANES data from children, these
data are encouraging in that no increases were observed in
the prevalence of obesity among adults. However, specific
subgroups did demonstrate increases in rates of obesity
including black and Mexican American women, suggesting
that targeted prevention interventions are warranted.
Summary written by: Elizabeth A. Jackson, MD
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